This official website is maintained by the Notice Administrator for the In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation (All End Payor Plaintiff Actions), MDL No 2503 1:14-md-2503-DJC, pending in the United States District Court of Massachusetts (the “Court”).

The information contained on this website is
only a summary. You may download a copy of the full Notice by clicking here.

If
you purchased Solodyn or its generic version,
a class action lawsuit may affect your rights.

A court authorized
this notice. This is not a solicitation from a lawyer.

A
lawsuit is pending in the United States District Court for the District of
Massachusetts (“the Court”) against the following Defendants: Medicis Pharmaceutical Corp., Impax
Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. Plaintiffs in
the lawsuit claim that Defendants hurt competition and violated state laws in
the United States and its territories, including Puerto Rico. Plaintiffs allege
Defendants unlawfully delayed the availability of allegedly less-expensive
generic versions of Solodyn and that Defendants’
conduct caused certain consumers and third-party payors
(discussed below) to pay too much for Solodyn in
these states and territories. Defendants deny any wrongdoing.

On
October 16, 2017, the Court determined that this case could proceed as a Class
Action.

This lawsuit does not claim that Solodyn is unsafe or ineffective.

CERTIFIED CLASS

You may be a member of the Class if, during
the period from July 23, 2009, until the alleged anticompetitive effects of
Defendants’ allegedly unlawful conduct cease (the “Class Period”):

•As
a Consumer, you purchased or paid for some or all of the purchase price
for Solodyn 45mg, 55mg, 65mg, 80mg, 90mg, 105mg,
115mg, and/or 135mg tablets and/or generic versions of one or more of these
dosages, for consumption by yourself or your family, other than for resale, in
Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho,
Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota,
Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey,
New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode
Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia,
Wisconsin, Wyoming, the District of Columbia and Puerto Rico.

•As
a Third-Party Payor, you purchased, paid
and/or reimbursed for some or all of the purchase price for Solodyn
45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg tablets and/or generic
versions of one or more of these dosages, for consumption by your members,
employees, insureds, participants, or beneficiaries,
other than for resale, in Alabama, Alaska, Arizona, Arkansas, California,
Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine,
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska,
Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North
Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont,
Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and
Puerto Rico.

The following persons or entities are
excluded from the End-Payor Class: (a) Defendants and
their counsel, officers, directors, management, employees, subsidiaries, or
affiliates; (b) All federal or state governmental entities, excluding cities,
towns, or municipalities with self-funded prescription drug plans; (c) All
persons or entities that purchased Solodyn or its
generic equivalents for purposes of resale or directly from the Defendants or
their affiliates; (d) Fully insured health plans (plans that purchased
insurance from another third-party payor covering
100% of the plan’s reimbursement obligations to its members); (e) Pharmacy
Benefits Managers; (f) Flat co-payers (consumers who paid the same co-payment
amount for brand and generic drugs); and (g) The judges in this case and any
members of their immediate families.

Please check this website for additional
updates.

YOURLEGALRIGHTSANDOPTIONS

EXCLUDE YOURSELF
FROM THE CLASS

This option allows you
to exclude yourself from the Class and instead file a lawsuit against the Defendants
asserting claims related to the allegationsor claimsinthis case.Theexclusiondeadlineis February 10, 2018.

do nothing

Give up rights to be part of any other lawsuit that asserts
claims related to the allegations or claims against the Defendants in this
case.

You will
need Adobe Reader to view documents on this site. You can learn more about Adobe
Reader and download the latest version by clicking here.